OTCMKTS: HCYT · Delayed Price · USD
+0.05 (2.04%)
Jun 2, 2023 4:00 PM EDT - Market closed

Company Description

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States.

The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders.

It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.

The company is headquartered in Tampa, Florida.

H-CYTE, Inc.
Country United States
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Michael W. Yurkowsky

Contact Details

2202 N. West Shore Blvd, Ste 200
Tampa, Florida 33607
United States
Phone 844-633-6839
Website hcyte.com

Stock Details

Ticker Symbol HCYT
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001591165
CUSIP Number 404124109
ISIN Number US4041241096
Employer ID 46-3312262
SIC Code 3841

Key Executives

Name Position
Michael W. Yurkowsky Chief Executive Officer and Director
Jeremy D. Daniel Chief Financial Officer
Dr. Tanya Rhodes Ph.D. Chief Scientific Officer
Jeffery Wright CPA, CPA Controller and Principal Accounting Officer

Latest SEC Filings

Date Type Title
May 22, 2023 10-Q Quarterly Report
May 15, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 10, 2023 10-K Annual Report
Apr 18, 2023 8-K Current Report
Apr 3, 2023 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 2, 2023 8-K Current Report
Feb 10, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 28, 2022 8-K Current Report
Nov 14, 2022 10-Q Quarterly Report
Oct 7, 2022 8-K Current Report